What is the history of Febrile infection-related epilepsy syndrome - FIRES?

Febrile infection-related epilepsy syndrome (FIRES) is a rare, catastrophic form of new-onset refractory status epilepticus that typically follows a mild febrile illness in previously healthy children. First recognized in the early 21st century, the history of FIRES reflects a shift from viewing it as a simple post-viral complication to understanding it as a complex, immune-mediated encephalopathy.

How was FIRES first identified in medical literature?

While similar clinical presentations were observed for decades under terms like "acute encephalitis with refractory, repetitive partial seizures," the specific entity now known as Febrile infection-related epilepsy syndrome (FIRES) was formally characterized in the mid-2000s. Researchers, most notably Dr. T.R. van Baalen and colleagues in 2010, helped solidify the diagnostic criteria, distinguishing FIRES from standard viral encephalitis by the persistent, treatment-resistant nature of the seizures that emerge days or weeks after the initial fever subsides.

How has our understanding of FIRES evolved?

Historically, clinicians often misdiagnosed FIRES as viral encephalitis or autoimmune encephalitis. However, modern research has shifted the focus toward a "cytokine storm" hypothesis, where the initial infection triggers a hyper-inflammatory response in the brain. Advancements in neuro-immunology and genetics have helped rule out primary viral infections as the direct cause, leading to the current consensus that FIRES is likely an immune-mediated condition rather than an active infection.

What are the major milestones in managing FIRES?

Treatment for FIRES remains challenging, but the landscape has evolved significantly. Milestones include:

• Early Era: Reliance on high-dose benzodiazepines and standard anti-seizure medications, which were largely ineffective.


• Middle Era: The introduction of aggressive immunotherapy, including intravenous immunoglobulin (IVIG), steroids, and plasma exchange.


• Modern Era: The use of ketogenic diet therapy as a cornerstone of treatment, often initiated early in the acute phase of FIRES.


• Experimental Phase: Emerging use of IL-1 receptor antagonists (like anakinra) to target the inflammatory pathways involved in FIRES.

How has patient advocacy changed the landscape?

Patient advocacy has been instrumental in raising awareness for this rare condition. With 65 members currently sharing their experiences on DiseaseMaps.org, the community has provided vital data that helps researchers track outcomes and advocate for specialized pediatric epilepsy protocols. This collective voice has pushed FIRES out of obscurity and into the focus of international clinical research consortia.

Next steps

• Consult with a board-certified pediatric epileptologist or a neuro-immunologist.


• Connect with the 65 members of the DiseaseMaps.org community to share clinical experiences and coping strategies.


• Inquire with your care team about clinical trials focusing on neuro-inflammation.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Febrile infection-related epilepsy syndrome.


• Orphanet: Rare disease database entry for FIRES.


• The International League Against Epilepsy (ILAE): Guidelines on new-onset refractory status epilepticus (NORSE) and FIRES.